Winnie Lei

Keywords autologous and allogeneic immunogenicity cell therapies human primary organoids cholangiocyte humanized mouse model transplantation immunology spatial transcriptomics NanoSeq Introduction Regenerative cellular therapies have emerged as a promising approach for the repair or replacement of diseased or damaged tissues and cells.1,2,3 The predominant strategy for the generation of therapies is differentiating embryonic stem cells (ESCs) or genetically modified induced pluripotent cells...

Abstract Developing an efficient and safe therapy necessitates a mechanistic understanding of the complex underlying pathology and manipulation of the multiple pathways at the molecular and genetic level. Network-based simulation of chronic myeloid leukemia (CML), a relatively well-understood cancer model, revealed the dynamics of simultaneously expressing pro-apoptotic BIM and silencing pro-survival MCL-1 in combination with the BCR-ABL-targeted tyrosine kinase inhibitor dasatinib.

Abstract Primary human cells cultured in organoid format have great promise as potential regenerative cellular therapies. However, their immunogenicity and mutational profile remain unresolved, impeding effective long-term translation to the clinic.